SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
87 42 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
87>>>> asked by the company to change its business description in the tuck1August 31
86So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-August 31
85I wonder about the CD200 program. There doesn't seem to be the same level oftuck-August 4
84So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-July 5
83That occurred to me, and may be a part of it. So far, the in vivo experiments htuck-June 26
82 >>>Then inexplicably off 10% today to new lows. Could be end-of-quartBulbaMan-June 26
81PD-1 combo now being studied. With Nivolumab, as an expansion of the ongoing P1tuck-June 26
80Updating the Novimmune bispecific effort. In addition to the CD47/CD19 bispeciftuck-April 4
79Can't find the post, but somewhere around here I said that it was possible tscaram(o)uche-March 31
78Here is another anti-CD47/PD-1 combo study, this time in a model of esophogeal ctuck-March 27
77Thanks for pointing, I did not saw early. Seams that priority date was 2008!Miljenko Zuanic-March 6
76Lead finding technology is in the lead finding stage..... synthon.com Shockingscaram(o)uche-March 5
75The sanquin stuff looks, first blush, like it was written to exclude anything rescaram(o)uche-March 5
74Timely find, too: Synthon just licensed it. Synthon enters worldwide exclusive tuck-March 3
73When cancer is drug target, I am not much concerned about legal IP right and figMiljenko Zuanic-March 2
72Good find, Miljenko. Not sure how this squares against TRIL's IP. Van den tuck-March 2
71One of the competitor: sanquin.nlMiljenko Zuanic-March 2
70 Thanks Tuck. Judging by TRIL’s less than enthusiastic stock response to the PR BulbaMan-February 24
69 Tuck: Any comments on today’s TRIL PR re: latest CD47 results? It confirms stuck-February 24
68 Tuck: Any comments on today’s TRIL PR re: latest CD47 results? Peace & goodBulbaMan-February 24
67Effects of TTI-621 (SIRPaFc) on CD47 and serum cytokines associated with phagocytuck-February 22
66 Thank you! Yes, I learned of the G4 construct some time ago. Thanks. >&gscaram(o)uche-February 20
65 TTI-621 (SIRPaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broatuck-February 16
64Synergy with PD-L1 Durable antitumor responses to CD47 blockade require adaptivtuck-12/5/2016
63Sorry, thought that last article was a freebie, but it's not. Parsing it motuck-12/5/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.